Sino Biopharm Wins China Approval for First-in-Class Myelofibrosis Drug

Sino Biopharmaceutical ( (HK:1177) ) has issued an announcement.

Sino Biopharmaceutical has secured Chinese marketing approval for rovadicitinib tablets, branded Anxu, a first-in-class dual JAK/ROCK small-molecule inhibitor for first-line treatment of intermediate-2 or high-risk myelofibrosis and related conditions. The drug’s dual anti-inflammatory and anti-fibrotic mechanism, coupled with favorable Phase II data showing superior efficacy and lower discontinuation versus standard therapy, positions it as a potentially transformative option in a rapidly expanding Chinese myelofibrosis market.

The approval strengthens the group’s innovative drug pipeline and could materially enhance its standing in hematology, with implications for revenue growth as myelofibrosis cases in China are projected to rise sharply. Rovadicitinib is also advancing in chronic graft-versus-host disease, including Phase III development in China and Phase II studies in the U.S., signaling broader international ambitions and reinforcing Sino Biopharmaceutical’s push into high-value, breakthrough therapies.

The most recent analyst rating on (HK:1177) stock is a Hold with a HK$7.90 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.

More about Sino Biopharmaceutical

Sino Biopharmaceutical Limited is a Hong Kong–listed pharmaceutical group focusing on the research, development, manufacturing and marketing of innovative drugs for major diseases. The company targets high-need therapeutic areas in China and globally, with a growing portfolio of oncology, immunology and other specialty treatments aimed at expanding its position in advanced biopharmaceuticals.

YTD Price Performance: -2.10%

Average Trading Volume: 62,411,416

Technical Sentiment Signal: Buy

Current Market Cap: HK$108.2B

For a thorough assessment of 1177 stock, go to TipRanks’ Stock Analysis page.